From the Journals

Gene associated with vision loss also linked to COVID: Study


 

FROM THE JOURNAL OF CLINICAL MEDICINE

Researchers have found a genetic link between the risk for COVID-19 infection and the leading cause of vision loss among people age 50 and older, age-related macular degeneration.

The findings show that COVID and AMD were associated with variations in what is called the PDGFB gene, which has a role in new blood vessel formation and is linked to abnormal blood vessel changes that occur in AMD. The study was published in the Journal of Clinical Medicine. The analysis included genetic data from more than 16,000 people with AMD, more than 50,000 people with COVID, plus control groups.

Age-related macular degeneration is a vision problem that occurs when a part of the retina – the macula – is damaged, according to the American Academy of Ophthalmology. The result is that central vision is lost, but peripheral vision remains normal, so it is difficult to see fine details. For example, a person with AMD can see a clock’s numbers but not its hands.

“Our analysis lends credence to previously reported clinical studies that found those with AMD have a higher risk for COVID-19 infection and severe disease, and that this increased risk may have a genetic basis,” Boston University researcher Lindsay Farrer, PhD, chief of biomedical genetics, explained in a news release.

Previous research has shown that people with AMD have a 25% increased risk of respiratory failure or death due to COVID, which is higher than other well-known risk factors such as type 2 diabetes (21%) or obesity (13%), according to the news release.

A version of this article first appeared on WebMD.com.

Recommended Reading

Hip fractures likely to double by 2050 as population ages
Clinician Reviews
Walking intensity and step count are linked to health benefits
Clinician Reviews
Home BP monitoring in older adults falls short of recommendations
Clinician Reviews
Online yoga program improves physical function in OA
Clinician Reviews
Frailty poses no limit to HFpEF meds
Clinician Reviews
Is another COVID-19 booster really needed?
Clinician Reviews
Does subclinical hyperthyroidism raise fracture risk?
Clinician Reviews
Prednisone, colchicine equivalent in efficacy for CPP crystal arthritis
Clinician Reviews
U.S. flu activity already at mid-season levels
Clinician Reviews
Heart benefits begin at well under 10,000 daily steps
Clinician Reviews